Claims for Patent: 5,403,830

Summary for Patent: 5,403,830

Title:	Compositions and methods of treating gastrointestinal disorders
Abstract:	The present invention relates to pharmaceutical compositions useful for treating or preventing gastrointestinal disorders. These compositions comprise a bismuth-containing agent, preferably a campylobacter-inhibiting bismuth-containing agent such as bismuth subsalicylate and bismuth subcitrate, and a histamine-2 receptor blocking anti-secretory agent such as cimetidine. The present invention further relates to methods for treating or preventing gastrointestinal disorders in humans or lower animals by administering a bismuth-containing agent and a histamine-2 receptor blocking anti-secretory agent.
Inventor(s):	Place; Geoffrey (Cincinnati, OH)
Assignee:	The Proctor & Gamble Company (Cincinnati, OH)
Application Number:	07/821,244
Patent Claims:	1. Pharmaceutical compositions useful for treating or preventing gastrointestinal disorders, said compositions comprising: (a) a safe and therapeutically effective amount of a bismuth-containing agent; (b) a safe and therapeutically effective amount of an H.sub.2 receptor blocking anti-secretory agent; and (c) a pharmaceutically-acceptable carrier. 2. Pharmaceutical compositions useful for treating or preventing gastrointestinal disorders, according to claim 1, wherein the bismuth-containing agent is selected from the group consisting of bismuth aluminate, bismuth subcarbonate, bismuth subcitrate, bismuth citrate, tripotassium dicitrato bismuthate, bismuth subgalate, bismuth subnitrate, bismuth tartrate, bismuth subsalicylate, and mixtures thereof. 3. Pharmaceutical compositions useful for treating or preventing gastrointestinal disorders, according to claim 1, wherein the bismuth-containing agent is a campylobacter-inhibiting bismuth-containing agent. 4. Pharmaceutical compositions useful for treating or preventing gastrointestinal disorders, according to claim 3, wherein the campylobacter-inhibiting bismuth-containing agent is selected from the group consisting of bismuth subsalicylate, bismuth subcitrate, and mixtures thereof. 5. Pharmaceutical compositions useful for treating or preventing gastrointestinal disorders, according to claim 3, wherein the H.sub.2 receptor blocking anti-secretory agent is selected from the group consisting of cimetidine, ranitidine, and mixtures thereof. 6. Pharmaceutical compositions useful for treating or preventing gastrointestinal disorders, said compositions comprising: (a) a safe and therapeutically effective amount of a bismuth-containing agent selected from the group consisting of bismuth subsalicylate, bismuth subcitrate, and mixtures thereof; (b) a safe and therapeutically effective amount of an H.sub.2 receptor blocking anti-secretory agent selected from the group consisting of cimetidine, ranitidine, and mixtures thereof; and (c) a pharmaceutically-acceptable carrier. 7. Pharmaceutical compositions useful for treating or preventing gastrointestinal disorders, according to claim 6, wherein the bismuth-containing agent is bismuth subsalicylate, and the H.sub.2 receptor blocking anti-secretory agent is cimetidine. 8. Pharmaceutical compositions useful for treating or preventing gastrointestinal disorders, said compositions comprising: (a) from about 0.1% to about 99.8% of a bismuth-containing agent; (b) from about 0.1% to about 99.8% of an H.sub.2 receptor blocking anti-secretory agent; and (c) from about 0.1% to about 99.8% of a pharmaceutically-acceptable carrier. 9. Pharmaceutical compositions useful for treating or preventing gastrointestinal disorders according to claim 8, said compositions comprising: (a) from about 0.1% to about 99.8% of a bismuth-containing agent selected from the group consisting of bismuth subsalicylate, bismuth subcitrate, and mixtures thereof; (b) from about 0.1% to about 99.8% of an H.sub.2 receptor blocking anti-secretory agent selected from the group consisting of cimetidine, ranitidine, and mixtures thereof; and (c) from about 0.1% to about 99.8% of a pharmaceutically-acceptable carrier. 10. Pharmaceutical compositions according to claim 8 in unit dosage form comprising from about 50 mg to about 1500 mg of bismuth. 11. Pharmaceutical compositions according to claim 9 in unit dosage form comprising from about 50 mg to about 1500 mg of bismuth. 12. Pharmaceutical compositions according to claim 10 in unit dosage form comprising from about 1 mg to about 300 mg of an H.sub.2 receptor blocking anti-secretory agent. 13. Pharmaceutical compositions according to claim 9 in unit dosage form comprising from about 50 mg to about 500 mg of bismuth, and from about 1 mg to about 300 mg of ranitidine. 14. Pharmaceutical compositions according to claim 9 in unit dosage form comprising from about 50 mg to about 500 mg of bismuth, and from about 50 mg to about 300 mg of cimetidine. 15. Methods for treating or preventing gastrointestinal disorders in humans or lower animals, said methods comprising administering to a human or lower animal in need of such treatment or prevention a safe and therapeutically effective amount of a bismuth-containing agent and a safe and therapeutically effective amount of an H.sub.2 receptor blocking anti-secretory agent, and wherein said methods further comprise administering a bismuth-containing agent and an H.sub.2 receptor blocking anti-secretory agent within about one hour of each other. 16. A method for treating or preventing gastrointestinal disorders in humans or lower animals, according to claim 15, wherein the bismuth-containing agent and the H.sub.2 receptor blocking anti-secretory agent are both administered orally. 17. Methods for treating or preventing gastrointestinal disorders in humans or lower animals, according to claim 16, wherein the bismuth-containing agent is a campylobacter-inhibiting bismuth-containing agent. 18. Methods for treating or preventing gastrointestinal disorders in humans or lower animals, according to claim 17, wherein the campylobacter-inhibiting bismuth-containing agent is selected from the group consisting of bismuth subcitrate, bismuth subsalicylate, and mixtures thereof; and wherein further the H.sub.2 receptor blocking anti-secretory agent is selected from the group consisting of cimetidine, ranitidine, and mixtures thereof. 19. Methods for treating or preventing gastrointestinal disorders in humans or lower animals, according to claim 18, wherein the campylobacter-inhibiting bismuth-containing agent is bismuth subsalicylate, and the H.sub.2 receptor blocking anti-secretory agent is cimetidine. 20. Methods for treating or preventing gastrointestinal disorders in humans or lower animals, said methods comprising administering to a human or lower animal in need of such treatment or prevention a safe and therapeutically effective amount of a pharmaceutical composition according to claim 1. 21. Methods for treating or preventing gastrointestinal disorders in humans or lower animals, said methods comprising administering to a human or lower animal in need of such treatment or prevention a safe and therapeutically effective amount of a pharmaceutical composition according to claim 6. 22. Methods for treating or preventing gastrointestinal disorders in humans or lower animals, said methods comprising administering to a human or lower animal in need of such treatment or prevention a safe and therapeutically effective amount of a pharmaceutical composition according to claim 7. 23. A method for treating or preventing gastrointestinal disorders in humans or lower animals, said method comprising simultaneously dosing the gastrointestinal tract of the human or lower animal in need of such treatment or prevention with safe and therapeutically effective amounts of bismuth and ranitidine. 24. A method for treating or preventing gastrointestinal disorders in humans or lower animals, said method comprising simultaneously dosing the gastrointestinal tract of the human or lower animal in need of such treatment or prevention with safe and therapeutically effective amounts of bismuth and cimetidine. 25. A method for treating ulcers of the upper gastrointestinal tract in humans or lower animals, said method comprising simultaneously treating the upper gastrointestinal tract of the human or lower animal in need of such treatment with safe and therapeutically effective amounts of bismuth and ranitidine. 26. A method for treating ulcers of the upper gastrointestinal tract in humans or lower animals, said method comprising simultaneously treating the upper gastrointestinal tract of the human or lower animal in need of such treatment with safe and therapeutically effective amounts of bismuth and cimetidine. 27. A method for treating non-ulcerative gastrointestinal disorders in humans or lower animals, said method comprising simultaneously treating the upper gastrointestinal tract of the human or lower animal in need of such treatment with safe and therapeutically effective amounts of bismuth and ranitidine. 28. A method for treating non-ulcerative gastrointestinal disorders in humans or lower animals, said method comprising simultaneously treating the upper gastrointestinal tract of the human or lower animal in need of such treatment with safe and therapeutically effective amounts of bismuth and cimetidine. 29. A method for treating Campylobacter pyloridis infection of the upper gastrointestinal tract in humans or lower animals, said method comprising simultaneously treating the upper gastrointestinal tract of the human or lower animal infected with Campylobacter pyloridis with safe and therapeutically effective amounts of bismuth and ranitidine. 30. A method for treating Campylobacter pyloridis infection of the upper gastrointestinal tract in humans or lower animals, said method comprising simultaneously treating the upper gastrointestinal tract of the human or lower animal infected with Campylobacter pyloridis with safe and therapeutically effective amounts of bismuth and cimetidine. 31. A method for treating or preventing gastrointestinal disorders in humans or lower animals, said method comprising orally administering to a human or lower animal in need of such treatment or prevention a safe and therapeutically effective amount of a unit dose composition according to claim 10. 32. A method for treating or preventing gastrointestinal disorders in humans or lower animals, said method comprising administering to a human or lower animal in need of such treatment or prevention a safe and therapeutically effective amount of a unit dose composition according to claim 11. 33. A method for treating or preventing gastrointestinal disorders in humans or lower animals, said method comprising administering to a human or lower animal in need of such treatment or prevention a safe and therapeutically effective amount of a unit dose composition according to claim 13. 34. A method for treating or preventing gastrointestinal disorders in humans or lower animals, said method comprising administering to a human or lower animal in need of such treatment or prevention a safe and therapeutically effective amount of a unit dose composition according to claim 14. 35. A method for treating or preventing gastrointestinal disorders in humans or lower animals, said method comprising simultaneously treating, for from about 1 to about 60 days, the gastrointestinal tract of the human or lower animal in need of such treatment or prevention with from about 50 mg to about 5000 mg per day of bismuth and from about 1 mg to about 10 g per day of ranitidine. 36. A method for treating or preventing gastrointestinal disorders in humans or lower animals, said method comprising simultaneously treating, for about 1 to about 60 days, the gastrointestinal tract of the human or lower animal in need of such treatment or prevention with from about 50 mg to about 5000 mg per day of bismuth and from about 50 mg to about 5000 mg per day of cimetidine. 37. Methods for treating of preventing gastrointestinal disorders in human or lower animals, said methods comprising administering to a human or lower animal in need of such treatment or prevention a safe and therapeutically effective amount of a bismuth-containing agent and a safe and therapeutically effective amount of an H.sub.2 receptor blocking anti-secretory agent, and wherein said methods further comprise administering a bismuth-containing agent and an H.sub.2 receptor blocking anti-secretory agent within about five minutes of each other.